SEC Form 4 · accession 0001140361-17-041378

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Nov 3, 2017

Accepted (ET)

Nov 7, 2017 · 4:07 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Nov 3, 2017	M	11,508	$22.03	A	215,642	D
Common Stock^F1,F2	Nov 3, 2017	S	11,508	$42.50	D	204,134	D
Common Stock^F1	Nov 3, 2017	M	20,000	$14.44	A	224,134	D
Common Stock^F1,F3	Nov 3, 2017	S	20,000	$42.92	D	204,134	D
Common Stock^F4	holding	—	—		—	1,000	I	By Son

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5,F6	$22.03	Nov 3, 2017	M	11,508	D	—	Mar 14, 2018	Common Stock	11,508	0	D
Stock Option (Right to Buy)^F5,F6	$14.44	Nov 3, 2017	M	20,000	D	—	Mar 12, 2019	Common Stock	20,000	41,906	D

F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive.
F4The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F5Consists of an option granted under the company's stock incentive plan as amended and restated.
F6The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.